GLP-1
Patient Guide
Who we are ↗
About the publication

Here are the pages
behind the guide.

Original research October 5, provider reviews October 15, and scientific sources October 21, 2026. Open the current page when considering a changing offer.

Where the information comes from

Scientific sources checked October 21, 2026. Earlier research and provider sources retain their dated histories below. Provider pages describe their own offers; they do not independently prove the quality of care.

  1. Noom Med — program pricingProvider offer; branded-medication pathway reviewed
  2. Noom — Telehealth for Branded Meds prescriptions and pharmacyProvider workflow and medication-cost terms
  3. Found — offer terms for new membersProvider plan and billing terms
  4. NIDDK — talking with patients about weightFederal guidance for respectful clinical conversations
  5. FDA — buying medicine from an online pharmacyFederal consumer guidance
  6. CoreAge Rx — official treatment pagesProvider offer
  7. CoreAge Rx — tirzepatide offerProvider offer
  8. CoreAge Rx Help Center — Pricing & PlansProvider billing terms
  9. SuperHealthy Rx — current GLP-1 offerProvider offer
  10. Likeness Rx — GLP-1 plans and billingProvider offer
  11. Ro Body — membership and medication costsProvider offer
  12. WeightWatchers — Med+ membership and medicationProvider offer
  13. LillyDirect — pharmacy access and independent care optionsManufacturer access program
  14. FDA — concerns with unapproved GLP-1 drugsRegulator guidance
  15. FDA — compounding questions and answersRegulator guidance
  16. FDA — dosing errors with compounded injectable semaglutideSafety alert, July 2024
  17. NIDDK — prescription medications for overweight and obesityFederal patient education
  18. Prescription Medications to Treat Overweight & Obesity - NIDDKPrimary health resource; checked October 5, 2026
  19. What Should I Ask My Doctor During a Checkup?Primary health resource; checked October 5, 2026
  20. Weight Loss Care for Women, Built to Last | HersProvider public offer; checked October 5, 2026
  21. Medical Weight Loss Programs Available OnlineProvider public offer; checked October 5, 2026
  22. Choosing a Safe & Successful Weight-loss Program - NIDDKPrimary health resource; checked October 5, 2026
  23. Online weight loss medication with or without insuranceProvider public offer; checked October 5, 2026
  24. FAQs | HersProvider public offer; checked October 5, 2026
  25. It can be a lifesaving tool, especially during an emergencyPrimary health resource; checked October 5, 2026
  26. How It Works - PlushCareProvider public offer; checked October 5, 2026
  27. Weight Management Program Overview | LifeMD®Provider public offer; checked October 5, 2026
  28. Frequently Asked Questions | LifeMD®Provider public offer; checked October 5, 2026
  29. Programs & Membership Plans | LifeMD®️Provider public offer; checked October 5, 2026
  30. Restore Delivered: GLP-1 plans and studio inclusionsProvider public information; checked October 15, 2026
  31. Restore Delivered: Terms, April 2, 2026Provider public information; checked October 15, 2026
  32. Restore Delivered: Privacy policyProvider public information; checked October 15, 2026
  33. HumeCare: Public protocol offer and results claimsProvider public information; checked October 15, 2026
  34. HumeCare: Membership and results-guarantee terms, July 2, 2026Provider public information; checked October 15, 2026
  35. HumeCare: Privacy policyProvider public information; checked October 15, 2026
  36. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.Full primary post hoc analysis main text and main Table 1 reviewed; supplementary file and original trial protocols not independently reviewed. · Checked 2026-10-21
  37. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.Full primary post hoc report, Methods, Results, main Table 1 and Discussion/funding reviewed; supplementary tables and source-trial protocols not separately reviewed. · Checked 2026-10-21
  38. DailyMed: WEGOVY semaglutide current prescribing informationCurrent official DailyMed label, updated June 18, 2026, current archive June 30, 2026; indications, relevant safety sections 5.2, 5.3, 5.5, 5.6, 5.10, postmarketing experience and oral-drug interaction sections reviewed. Other sections not fully reviewed. · Checked 2026-10-21
  39. DailyMed: ZEPBOUND tirzepatide current prescribing informationCurrent official DailyMed label, updated August 28, 2026, current archive September 2, 2026; indications, relevant safety sections 5.2 through 5.5 and 5.9, postmarketing experience and oral-drug interaction sections reviewed. Other sections not fully reviewed. · Checked 2026-10-21